Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide

The European Respiratory Journal
M B LundJ Boe

Abstract

Long-term data on lung function after bone marrow transplantation (BMT) are inconclusive. Previously, a persistent reduction in gas transfer 1 yr after allogeneic BMT with busulphan and cyclophosphamide conditioning was reported by the current authors. In the present study this reduction was examined to see if it was permanent, transient or progressive. Prospectively, 43 consecutive adult patients with malignant blood disorders undertook lung function measurements prior to BMT, at 3 month intervals during the 1st yr after BMT and finally after 5 yrs. Mean baseline lung function values were >90% predicted. Within the 1st yr after BMT a transient decline in lung volumes and a persistent reduction in gas transfer were observed. After 5 yrs, baseline values were restored for all variables, except in four patients who developed obliterative bronchiolitis. Acute leukaemia and smoking were independently associated with gas transfer reductions at baseline and during the 1st yr after BMT. Allogeneic bone marrow transplantation with busulphan and cyclophosphamide conditioning was associated with a reduction in gas transfer 1 yr after bone marrow transplantation but baseline values were usually restored after 5 yrs. Since recovery may be ...Continue Reading

Citations

Oct 16, 2012·Bone Marrow Transplantation·A M HolmY Fløisand
Apr 29, 2014·Der Internist·E Wollmer, A Neubauer
Nov 3, 2005·Clinics in Chest Medicine·Bekele Afessa, Steve G Peters
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·David I MarksJ Douglas Rizzo
Mar 7, 2020·Pediatric Allergy, Immunology, and Pulmonology·Nusa MatijasicIvan Pavic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.